Min FangManaging Director, Co-Head of China Private Equity

Min Fang joined Warburg Pincus in 2007 and co-leads the firm’s private equity investments in China. Min is currently the Chairman of HTDK and serves on the boards of Insilico Medicine, Haihe Biopharma, Jinxin Fertility Group (01951. HK), Zhenshiming Pharmaceutical, Evercare, and Ziroom. Prior to joining Warburg Pincus, he worked at the Boston Consulting Group focusing on management consulting for pharmaceutical and medical device companies. Min received a BA in International Finance from Fudan University and an MBA from the Stanford Graduate School of Business.